top of page
Treating Cancer With Precision
News
Categories
Sign up
Featured Posts
Archive
Follow Us
Nov 10, 2022
Alpha Tau to Present at Upcoming November Investor Conferences
JERUSALEM, November 9, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the “Company”), the developer of the...
Oct 24, 2022
Alpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society
- Medicines and Healthcare products Regulatory Agency of the United Kingdom approves clinical trial in squamous cell carcinoma of the...
Sep 11, 2022
Acceptance in Major Peer-Reviewed Journals of two Landmark Pre-Clinical Studies
Alpha Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and...
Sep 6, 2022
Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer
JERUSALEM, September 1, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation...
Aug 31, 2022
Alpha Tau Medical to Participate in Upcoming September Investor Conferences
JERUSALEM, August 30, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer...
Aug 26, 2022
Alpha Tau Medical Announces Second Quarter 2022 - Financial Results and Provides Corporate Update
-Received FDA Conditional Investigational Device Exemption (IDE), whose conditions have since been satisfied, to initiate a pivotal trial...
Aug 22, 2022
Alpha Tau and MIM Software Announce Collaboration for Alpha DaRT Treatment Planning
JERUSALEM and CLEVELAND, Aug. 22, 2022 -- Today, Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative...
Jul 6, 2022
Alpha Tau Hosting Key Opinion Leader Meeting on Alpha DaRT Clinical Trials
Alpha Tau Hosting Key Opinion Leader Meeting on Alpha DaRT Clinical Trials
Jun 23, 2022
Alpha Tau Announces Treatment of First Prostate Cancer Patient with Alpha DaRT™
JERUSALEM, June 22, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer...
Jun 16, 2022
Receipt of Radioactive License to Allow Production in Main Manufacturing Floor at its Jerusalem Site
Alpha Tau Announces Receipt of Radioactive License to Allow Production in Main Manufacturing Floor at its Jerusalem Site, Amended...
bottom of page